Papers
4
Total Citations
79
H-Index
4
About
Martin Spahn is a leading urologic oncologist whose research centers on high-risk and oligometastatic prostate cancer, as well as innovative perioperative treatments for muscle-invasive urothelial carcinoma (MIUC). His major contributions include advancing the integration of immunotherapy with standard chemotherapy, as demonstrated in his landmark single-arm phase II trial (SAKK 06/17) evaluating durvalumab combined with cisplatin/gemcitabine for operable MIUC. This work, with 32 citations, highlights his role in shaping neoadjuvant strategies to reduce relapse rates. Spahn has also critically examined surgical outcomes, notably investigating whether positive surgical margins at radical prostatectomy are a surgeon-dependent predictor of prostate cancer death (6 citations) and clarifying the role of surgery for high-risk prostate cancer (28 citations). His review on newly diagnosed oligometastatic prostate cancer (13 citations) addresses key controversies and future directions in managing this challenging disease state. Through these studies, Spahn has influenced clinical decision-making and trial design, earning recognition as a key voice in urologic oncology. His work continues to guide researchers and clinicians toward more effective, personalized treatments for patients with genitourinary malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2Results of surgery for high-risk prostate cancer28 citations · 2013
- 3
- 4